Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
- Resource Type
- Article
- Authors
- Hanna, Michael G; Badrising, Umesh A; Benveniste, Olivier; Lloyd, Thomas E; Needham, Merrilee; Chinoy, Hector; Aoki, Masashi; Machado, Pedro M; Liang, Christina; Reardon, Katrina A; de Visser, Marianne; Ascherman, Dana P; Barohn, Richard J; Dimachkie, Mazen M; Miller, James A L; Kissel, John T; Oskarsson, Björn; Joyce, Nanette C; Van den Bergh, Peter; Baets, Jonathan; De Bleecker, Jan L; Karam, Chafic; David, William S; Mirabella, Massimiliano; Nations, Sharon P; Jung, Hans H; Pegoraro, Elena; Maggi, Lorenzo; Rodolico, Carmelo; Filosto, Massimiliano; Shaibani, Aziz I; Sivakumar, Kumaraswamy; Goyal, Namita A; Mori-Yoshimura, Madoka; Yamashita, Satoshi; Suzuki, Naoki; Katsuno, Masahisa; Murata, Kenya; Nodera, Hiroyuki; Nishino, Ichizo; Romano, Carla D; Williams, Valerie S L; Vissing, John; Auberson, Lixin Zhang; Wu, Min; de Vera, Ana; Papanicolaou, Dimitris A; Amato, Anthony A
- Source
- In The Lancet Neurology September 2019 18(9):834-844
- Subject
- Primary Research
Articles
- Language
- ISSN
- 1474-4422